The concept of apolipoprotein-defined lipoprotein families and its clinical significance

被引：62

作者：

Petar Alaupovic

机构：

[1] Lipid and Lipoprotein Laboratory, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104

来源：

Current Atherosclerosis Reports | 2003年 / 5卷 / 6期

关键词：

Fenofibrate; Plasma Lipoprotein; Arterioscler Thromb Vasc Biol; Lipoprotein Particle; Lipoprotein Subclass;

D O I：

10.1007/s11883-003-0036-8

中图分类号：

学科分类号：

摘要：

Classification of plasma lipoproteins on the basis of apolipoprotein (apo) composition recognizes two lipoprotein (Lp) classes, one of which is characterized by apoA-I and the other by apoB as major protein constituents. The former lipoprotein class consists of three major subclasses referred to (according to their apolipoprotein constituents) as Lp-A-I, Lp-A-I:A-II, and Lp-A-II, and the latter one of five subclasses called Lp-B, Lp-B:E, Lp-B:C, Lp-B:C:E, and Lp-A-II:B:C:D:E. As polydisperse systems of particles, the apoA-I-containing lipoproteins overlap in high-density segments and apoB-containing lipoproteins in low-density segments of the density gradient. Each subclass is characterized by a specific chemical composition and metabolic property. Normolipidemia and dyslipoproteinemias are characterized by quantitative rather than qualitative differences in the levels of apoA- and apoB-containing subclasses. Furthermore, apoA-containing subclasses seem to differ with respect to their relative antiatherogenic capacities, and apoB-containing subclasses regarding their relative atherogenic potentials. Whereas Lp-A-I may have a greater antiatherogenic capacity than other apoA-containing subclasses, the cholesterol-enriched Lp-B:C appears to be the most atherogenic subclass among apoB-containing lipoprotein families. The use of pharmacologic and/or dietary interventions to treat dyslipoproteinemias has already shown that these therapeutic modalities may affect selectively individual apolipoprotein-defined lipoproteins, and thus allow the selection of individualized treatments targeted at decreasing harmful and/or increasing beneficial lipoprotein subclasses. Copyright © 2003 by Current Science Inc.

引用

页码：459 / 467

页数：8

共 75 条

[31] Agnani C., Bard J.M., Candelier L., Et al., Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells, Arterioscler. Thromb., 11, pp. 1021-1029, (1991)
[32] Clavey V., Lestavel-Delattre S., Copin C., Et al., Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E, Arterioscler. Thromb. Vasc. Biol., 15, pp. 963-971, (1995)
[33] Koren E., Koscec M., Corder C., Et al., Differential atherogenicity of complex apoB-containing lipoprotein particles, Atherosclerosis, 109, pp. 217-218, (1994)
[34] Wallace R.B., Anderson R.A., Blood lipids, lipid-related measures and the risk of atherosclerotic cardiovascular disease, Epidemiol Rev., 9, pp. 95-119, (1987)
[35] Marz W., Trommlitz M., Gross W., Differential turbidimetric assay for subpopulations of lipoproteins containing apolipoprotein A-I, J. Clin. Chem. Clin. Biochem., 26, pp. 573-578, (1988)
[36] Alaupovic P., Tavella M., Fesmire J., Separation and identification of apoB-containing lipoprotein particles in normolipidemic subjects and patients with hyperlipoproteinemias, Adv. Exp. Med. Biol., 210, pp. 7-14, (1987)
[37] Alaupovic P., Koren E., Immunoaffinity chromatography of plasma lipoprotein particles, Analyses of Fats, Oils and Lipoproteins, (1991)
[38] Koren E., Puchois P., Alaupovic P., Et al., Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay, Clin. Chem., 33, pp. 38-43, (1987)
[39] Parra H.J., Mezdour H., Ghalim N., Et al., Differential electro-immunoassay of human LpA-I lipoprotein particles on ready-to-use plates, Clin. Chem., 36, pp. 1431-1435, (1990)
[40] Alaupovic P., Fesmire J.D., Hunninghake D., Et al., The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial, Atherosclerosis, 146, pp. 369-379, (1999)

← 1 2 3 4 5 6 7 8 →